PCOS and PMOS weight management in NYC and Long Island

PMOS (polyendocrine metabolic ovarian syndrome) is the 2026 consensus name for the condition commonly known as PCOS. Care can address cycles, metabolic health, symptoms and pregnancy plans.

Polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome, or PMOS, in 2026. Weight-management care can include lifestyle support, metabolic evaluation, metformin discussion, and anti-obesity medication when an adult independently meets the criteria and the safety review supports treatment.

Arranging your appointment

PCOS care can address cycles, metabolic health, symptoms, and pregnancy plans. Some newer material uses PMOS terminology, but a name change does not create a new approved drug indication. Treatment should follow the clinical diagnosis and your main goal.

PCOS and PMOS metabolic care

PMOS (polyendocrine metabolic ovarian syndrome) is the 2026 consensus name for the condition commonly known as PCOS. Care can address cycles, metabolic health, symptoms and pregnancy plans. Older records and government materials may still use PCOS. The name change does not create a new approved drug indication; treatment should follow the clinical diagnosis and your main goal.

How pCOS and PMOS metabolic care works

PCOS can involve irregular ovulation, androgen-related symptoms, and insulin resistance. Metformin and GLP-1 medicines act differently and are not substitutes for every goal. Improved metabolic health does not guarantee fertility.

Eligibility: PCOS and PMOS metabolic care

PCOS or insulin resistance alone does not establish an approved obesity-drug indication or payer coverage. A person with PCOS may qualify under the medicine’s obesity or diabetes criteria. Pregnancy plans may make weight-loss treatment unsuitable at this time.

What to expect: PCOS and PMOS metabolic care

Start with the main goal and pregnancy timeline. Review cycles, glucose, lipids, prior treatment, medicines, and fertility care. Discuss nutrition, metformin when appropriate, weight treatment under its own indication, and gynecology or fertility referral. Identify who manages each part of care.

Preparing for your appointment

Bring cycle and pregnancy history, glucose and lipid results, medicines, supplements, prior authorization denials, and the desired pregnancy timeline. Irregular cycles do not rule out pregnancy.

Risks and when to seek help

Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs emergency department assessment now. Call 911 for breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. For weight treatment, semaglutide should be stopped at least two months before planned pregnancy. Tirzepatide requires additional or non-oral contraception for four weeks after starting or increasing. Foundayo uses a 30-day precaution. Contact the prescriber promptly after a positive pregnancy test.

Follow-up and treatment review

Review metabolic outcomes, cycle changes, tolerability, contraception, and pregnancy plans. Discuss interruptions and restarting after pregnancy or breastfeeding with the prescriber. Continue fertility or gynecology care when needed.

Appointments, costs and coverage

Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.

Questions about your care

Is PCOS now called PMOS?

PMOS means polyendocrine metabolic ovarian syndrome, the 2026 consensus name for the condition commonly called PCOS. The Endocrine Society announced the name change on May 12, 2026, and ASRM endorsed it on May 27. NICHD’s current patient guidance still uses PCOS, so both names may appear in records and information. Ask how your clinician documents the diagnosis. The name change does not create a new drug indication or guarantee insurance coverage.

Are GLP-1 medicines approved to treat PMOS or PCOS?

GLP-1 medicines do not have a dedicated US PCOS or PMOS indication in current US labels. A person with PCOS may qualify under the selected product’s obesity or diabetes indication after clinical review. PCOS alone does not guarantee a prescription or insurance coverage; review the actual treatment goal and criteria.

Can a woman with PMOS or PCOS and obesity be evaluated for Wegovy or Zepbound?

Yes, an evaluation may be appropriate under the medicine’s obesity indication. The clinician still reviews safety, pregnancy plans, current treatment, and clinical criteria. PCOS does not guarantee a prescription or insurance approval.

Does PMOS or PCOS automatically qualify for insurance coverage?

No. PCOS or PMOS does not automatically qualify someone for GLP-1 insurance coverage. The plan considers the exact medicine, diagnosis and its benefit criteria. Ask about an appropriate approved obesity or diabetes indication and required records; the terminology change itself creates neither a drug indication nor a coverage entitlement.

Can weight-loss medication improve fertility?

Metabolic or weight changes may affect cycles and ovulation, but response varies and pregnancy is not guaranteed. Irregular cycles do not prevent pregnancy reliably. Review contraception and pregnancy goals with the clinician. GLP-1 weight-loss treatment is not an approved infertility treatment.

Is metformin the same as a GLP-1 medicine?

Semaglutide activates GLP-1 receptors; tirzepatide activates GIP and GLP-1 receptors. Their diabetes and weight brands have different indications and instructions. Foundayo contains orforglipron, another GLP-1 medicine. Metformin acts differently. Choose the exact medicine for the clinical goal rather than treating them as interchangeable.

What should I bring to the first visit?

Bring cycle and pregnancy history, glucose and lipid results, medicines, supplements, prior authorization denials, and the desired pregnancy timeline. Irregular cycles do not rule out pregnancy.

Medical sources

Important distinction: Wegovy, Zepbound, Saxenda, and other GLP-1-based obesity medicines are not FDA approved to treat PMOS or PCOS itself. They may be considered for chronic weight management when the patient meets the medicine's general obesity indication and the clinician confirms safety.

Medication options have different jobs

Metformin

The international guideline supports considering metformin for metabolic and anthropometric outcomes in adults with PCOS and higher BMI. It is not an FDA-approved weight-loss drug.

Semaglutide or liraglutide

The guideline says GLP-1 receptor agonists may be considered for higher weight under general obesity rules. Wegovy and Saxenda have weight-management indications. Product and eligibility matter.

Tirzepatide

Zepbound is a dual GIP and GLP-1 receptor agonist approved for chronic weight management in eligible adults, not specifically for PMOS or PCOS.

Nutrition and activity

Lifestyle support remains part of care, while goals should be individualized, respectful, and valuable even when weight does not change quickly.

Women's health care

Irregular cycles, contraception, abnormal bleeding, pregnancy goals, and other gynecologic concerns may need a parallel women's-health plan.

Specialist referral

Complex endocrine disease, infertility treatment, eating disorders, pregnancy, or another concern may need endocrinology, gynecology, reproductive medicine, or behavioral-health care.

Start in NYC or Long Island